Objectives: Despite plasma virologic suppression with antiretroviral therapy (ART), HIV persists in gut tissue. The objectives of this study were to compare plasma and rectal tissue HIV RNA dynamics and to assess relationships with dolutegravir (DTG) plasma and tissue concentrations.
Background
Despite potent combination antiretroviral therapy (ART), HIV eradication has not been accomplished.
HIV persists in reservoirs, defined as a cell type or anatomical site where replication-competent virus accumulates and persists [1] . Gut-associated lymphoid tissue (GALT), the largest component of the human lymphoid organ system [2] , remains a suspected HIV reservoir.
Standard of care is lifelong ART, achieving HIV plasma viral load suppression, improvement in immunologic function, and reduction of HIV-associated morbidity. First-line ART recommendations by the Department of Health and Human Services (DHHS) for naive patients include using two nucleoside reverse transcriptase inhibitors (NRTIs) in combination with an integrase strand transfer inhibitor (INSTI) [3] . The secondgeneration INSTI dolutegravir (DTG, 50 mg daily), is recommended for naive patients in three ART regimens: DTG with tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or tenofovir alafenamide (TAF)/FTC and the fixed combination DTG/abacavir (ABC)/lamivudine (3TC)] [3] . With unboosted daily dosing and high barrier to resistance, DTG remains an attractive option for providers and patients and is being launched by the World Health Organization as a low-cost once daily generic in low-income and middle-income countries [4] .
Despite rapid plasma virologic suppression with INSTIs, HIV RNA viral dynamics within tissues such as the gut have not been well defined. Evidence shows that antiretrovirals may insufficiently penetrate sites outside plasma because of disposition and distribution determined by drug and host factors including sex, physiochemical properties, and membrane transporter effects [5] . For example, rectal tissue concentrations of DTG were less than 20% of plasma in HIV seronegative men [6] . There is conflicting evidence as to whether suboptimal antiretroviral drug penetration impacts reservoir viral dynamics: one study showed an association between lower antiretroviral drug concentrations in lymphatic tissues (including rectum) and persistent HIV replication [7] , whereas another study showed no correlation between drug concentrations and HIV RNA or DNA in GALT [8] . Our study aims were two-fold: compare early HIV RNA viral dynamics in plasma and rectal tissue following initiation of DTG-based ART, and explore relationships between rectal tissue HIV RNA decline and DTG exposure in both plasma and rectal tissue. We hypothesized that HIV RNA viral decay would be slower in rectal tissue than plasma and positively correlated with DTG exposure.
Methods
Study design and eligibility criteria Data was collected from treatment-naïve HIV-infected men and women enrolled into an ongoing 12-week prospective longitudinal cohort study within the Grady Infectious Diseases Program (IDP) in Atlanta, Georgia, USA, between February 2015 and September 2017 (NCT 02924389). A 12-week duration was chosen based on prior data showing that more than 80% of ART-naive patients initiating a DTG-based regimen achieved plasma virologic suppression at 8 weeks [9] . HIV-1 infected adult men and women were recruited from Grady IDP, other HIV clinics within metropolitan Atlanta, and the Atlanta site of the previously described Women's Interagency HIV Study (WIHS) cohort [10] through fliers and interaction with study staff. Eligibility criteria included: age at least 18 years; never having at least 30 consecutive days of ART and none in past 6 months; documented plasma HIV-1 RNA greater than 1000 copies/ml; normal renal and liver chemistries within 90 days; able and willing to give informed consent, able and willing to initiate firstline DTG-ART, and willing to undergo serial blood and rectal tissue sampling. Exclusion criteria included: pregnancy, severe anal/rectal disease, concurrent medications interacting with ART, bleeding diathesis, or medical condition that interfered with study conduct.
Type of DTG-ART was selected and prescribed by the participant's personal HIV provider. Participants were instructed to fill ART at their preferred pharmacy but refrain from starting medication until their first visit. All participants brought their own ARVs to each visit. Participants underwent paired plasma and rectal tissue sampling at four time points: baseline (pre-ART), and postARTat weeks 2 (Days 7, 10, or 14), 6, and 12. Paired rectal tissue and plasma samples were collected at random times post-ART dosing: 16 of 32 (50%) pairs were collected within 30 min to 6 h postdose, 16 of 32 (50%) of pairs were collected between 12 and 24 h postdose. In addition, intensive plasma pharmacokinetic sampling was performed at DTG first dose and steady state (week 12) at hours 1, 2, 3, 4, 6, 8, 24. Participants were counseled not to place anything per rectum for at least 7 days post-biopsy. Complete blood counts, comprehensive chemistries, and CD4 þ lymphocyte counts were performed at baseline and week 12. The Emory University Institutional Review Board (IRB) and the ethics committee for Grady Memorial Hospital (Grady Research Oversight Committee) approved this study. Informed consent was obtained from all study participants prior to study procedures.
Blood and rectal tissue sampling and processing Study visits occurred either at Grady IDP or Grady Memorial Hospital within the Clinical Research Unit of the Georgia Clinical and Translational Science Alliance. All participants had witnessed administration of DTG-ART at baseline and week 12. At weeks 2 and 6, adherence to ARTwas self-reported. Blood was obtained via venipuncture in four 10 ml sodium citrate cell preparation tubes and spun at 2300 rpm for 20 min. Plasma was centrifuged again at 2300 rpm for 10 min to remove erythrocytes, then stored at À80 8C. To acquire rectal tissue, a 10 cm plastic anoscope was inserted, rectal mucosa was visualized using a colposcope, and up to eight random punch biopsies (2.3 Â 4.2 mm) were obtained using mini-Tischler forceps. Rectal tissue was placed immediately in cryovials, snap frozen in liquid nitrogen, and stored at À80 8C.
HIV-1 RNA quantitation
Plasma and rectal tissue HIV-1 RNA quantitation was performed at the Emory Center for AIDS Research Virology and Molecular Biomarkers Core Laboratory using the Abbott Real-Time HIV-1 Assay with detectable range of 40-10 000 000 copies/ml. The rectal tissue HIV RNA assay was developed and optimized with methodologies used previously in other biological matrices [11] . Rectal tissue was weighed, combined with 500 ml of Promega lysis buffer and 25 ml Abbott Proteinase K, and incubated at 56 o C until dissolved. The supernatant was removed, volume brought up to 1 ml with phosphate-buffered saline, and run on the Abbott Realtime HIV-1 assay with results reported as RNA copies per gram.
Dolutegravir concentrations
DTG plasma and rectal tissue concentrations were measured at the University of Alabama-Birmingham's (UAB) Clinical Pharmacology Laboratory with high performance liquid chromatography-tandem mass spectroscopy (HPLC-MS-MS). DTG plasma concentrations were measured using methods previously developed by our team [12] . DTG and labeled DTG ( 15 N 2 H 7 , the internal standard) were extracted from 50 ml human tissue homogenate using protein precipitation with acetonitrile. Extracts were analyzed by reverse-phase chromatography using an ACE Excel 3 C18-PFP column under isocratic conditions at a flow rate of 500 ml/min at 40 8C with mobile phases A and B consisting of 0.1% formic acid in water and 0.1% formic acid acetonitrile, respectively. A triple quadrupole mass spectrometer (AB Sciex 5000) equipped with TurboV IonSpray operating in positiveion mode was used. Column effluents were analyzed by multiple reaction monitoring (MRM). The precursor/ product transitions were 420.1 ! 277.3 m/z for DTG and 428.1 ! 283.3 m/z for internal standard. The calibration curve was fit using weighted (1/x 2 ) linear regression analysis of DTG/internal standard peak area ratio versus DTG concentration from 5 to 5000 ng/ml. Assays were validated using the Guidance for Industry for US Federal Drug Administration (FDA) regulated studies with 5.5% coefficient of variation and lower and upper limits of quantitation 5-5000 ng/ml or ng/g.
Statistical analyses
Clinical and demographic characteristics were summarized by descriptive statistics with counts and percentages for categorical variables and medians and first and third quartiles (Q1, Q3) or range (minimum-maximum) for continuous variables. Noncompartmental pharmacokinetic analyses were performed for first dose and steady-state DTG using Phoenix Win Nonlin v8.0 (Certara, L.P, St. Louis, Missouri, USA). The area under the plasma concentration curve over the 24-h dosing interval (AUC 0-24h ) was computed using the linear trapezoidal method. Maximum plasma concentration (C max ), time to C max (T max ), and plasma concentration at the end of the dosing interval (C t ) were determined by visual inspection of the plasma concentration time curve. 24-h DTG concentrations were missing for three participants, and interpolated values were determined using the calculated slope of the terminal linear phase. Results below the assay's limit of detection were imputed as zero for first dose pharmacokinetics and half the lower limit of quantitation for steady-state pharmacokinetics. Correlation between repeated measures variables by site were computed from mixed models with random and repeated effects for site.
To calculate DTG rectal : plasma concentration ratios, rectal DTG concentrations were converted from ng/g to ng/ml assuming a tissue density of 1.06 ng/ml, then divided by plasma DTG concentrations. Median rectal tissue DTG concentrations were compared at weeks 2, 6, and 12 using Wilcoxon Signed Rank test.
To determine whether DTG concentrations predicted rectal tissue RNA suppression, we performed two different analyses. First, we developed binary logistic regression models accounting for repeated measures where the event is rectal RNA suppression. A variance component covariance structure was assumed, and logtransformed plasma, rectal, and rectal : plasma DTG concentration ratios were evaluated separately as predictors. Second, we compared pharmacokinetic parameters, including first dose and steady state DTG AUC 0-24 , and steady-state rectal tissue concentrations at weeks 2, 6, and 12, between those who had baseline detectable rectal tissue HIV RNA and achieved rectal tissue HIV-1 RNA suppression at any time point (rectal tissue suppressors) versus participants with persistent detectable rectal tissue HIV-1 RNA (rectal tissue nonsuppressors) using Wilcoxon Rank Sum Tests. Finally, demographic and clinical characteristics between rectal tissue suppressors and nonsuppressors were compared using chi-square or Fisher's exact tests for categorical variables and Wilcoxon Rank Sum Test for continuous variables.
All statistical analyses were performed using SAS version 9.4 software (Cary, North Carolina, USA), with an alpha level of 0.05.
Role of the funding source
The study sponsors had no role in study design; collection, analysis, and interpretation of data; writing of the report; or in the decision to submit the article for publication.
Results
Demographic and clinical characteristics Seventy-one individuals were assessed for eligibility; 21 were ineligible (12 not ART-naive, eight had severe anal/ rectal disease, one desired other ART), 37 decline to participate, and 13 were enrolled. Twelve participants completed at least two study visits and were included in the analyses. þ cell count 279 cells/ml (Q1 150, Q3 371), and plasma HIV RNA was 4.5 log copies/ml (Q1 3.8, Q3 4.9). Most participants (58.3%) received TDF/FTC as their NRTI backbone.
HIV-1 RNA quantitation Forty-two paired plasma and rectal tissue samples were available for HIV RNA analysis, with each participant providing at least two pairs. Fifty percent (6/12) of participants had HIV RNA below the assay's limit of detection in plasma by week 2, and all participants (100%) were undetectable in plasma by week 6 (Fig. 1a) . In contrast, only four of 12 (33.3%) participants achieved undetectable HIV RNA in rectal tissue at any time point: participant 1 became undetectable at week 12, participant 5 was undetectable at week 6 but had rebound detectable rectal RNA at week 12, and participants 4 and 9 had persistent undetectable rectal RNA at three consecutive time points (Fig. 1b) . Median log rectal tissue RNA at weeks 6 and 12 was 5.4 copies/g (Q1, 1.3, Q3, 5.7) and 4.7 (2.0-5.5), respectively. (Q1 15,133, Q3 30,845) . Steady-state plasma pharmacokinetic data was available for nine of 12 participants: C max was 2337 ng/ml (Q1 1842-3035), T max 3.0 h (Q1 3.0-4.0), C t 560 ng/ml (Q1 435.6, Q3 1210), and AUC 0-24h was 27 240 h ng/ml (Q1 24 475, Q3 48 075).
Thirty-two of 42 plasma and rectal tissue pairs were collected after at least 7 days of daily DTG administration and analyzed for steady-state DTG concentrations, with each participant providing at least one pair. DTG was detectable in 31 of 32 pairs (96.9%) of plasma and rectal tissue samples. Median DTG concentrations were significantly higher in plasma compared with rectal tissue at week 2: 1880 ng/ml (Q1 1106, Q3 3921) versus 807 ng/ml (Q1 646, Q3 1420), P ¼ 0.02, and week 6: 2810 ng/ml (Q1 697, Q3 4010) versus 661 ng/ml (Q1 271, Q3 1452), P ¼ 0.007, and nonsignificantly higher at week 12: 1142 ng/ml (Q1 614, Q3 1484) versus 365 ng/ ml (Q1 163, Q3 510), P ¼ 0.06. There was a moderateto-strong positive correlation between paired BP and rectal tissue DTG concentrations: r ¼ 0.76. There were no statistically significant differences in DTG rectal tissue, plasma, or rectal tissue:plasma concentration ratios at time points where rectal tissue RNA was undetectable versus detectable (Table 2) .
Rectal tissue RNA suppressors versus nonsuppressors
Characteristics of participants with baseline detectable rectal tissue HIV RNA who achieved rectal tissue HIV RNA suppression at any time point, n ¼ 3, were compared with rectal tissue HIV RNA nonsuppressors, n ¼ 8. All three (100.0%) rectal tissue suppressors compared with three of eight (37.5%) nonsuppressors were women. Compared with rectal tissue nonsuppressors, rectal tissue suppressors were older, with a median age of 52.4 years (range 50.5-54.2) versus 36.9 (24.3-53.6), P ¼ 0.05, had higher median baseline BMI, 35.9 kg/m 2 (range 24.9-38.5) versus 20.6 (17.7-29.9), P ¼ 0.05, and lower baseline log plasma HIV RNA: 3.7 cop/ml (range 3.6-4.4) versus 4.7 (3.8-5.4), P ¼ 0.02. There was a trend toward lower baseline log rectal tissue HIV RNA in rectal tissue suppressors compared with nonsuppressors: 5.4 log copies/ml (range 4.4-5.6) versus 6.8 (4.9-8.3), P ¼ 0.08 (Table 3) . No statistically significant differences were seen between rectal tissue suppressors and nonsuppressors with regard to first dose or steady state plasma AUC 0-24 h (Fig. 2) , or steady-state rectal tissue concentrations (Table 3) .
Discussion
To our knowledge, this is the first study to show detailed early HIV RNA viral dynamics in plasma and rectal tissue following initiation of DTG-based ART in naive men and women. Plasma virologic suppression with DTGbased therapy was rapid in all participants, consistent with what we know regarding INSTI potency [13] . In contrast, two-third of participants had persistent detectable HIV RNA in rectal tissue, even after achieving plasma virologic suppression. This is consistent with prior data showing recovery of HIV RNA from rectal tissue (ranging from 4.0 to 7.0 log copies RNA/g) at 3 months despite plasma suppression in non-INSTI ART regimens [7] . One-third of participants achieved HIV rectal tissue suppression at some point within the first 12 weeks of DTG-ART. In contrast, Asmuth et al. rectal tissue, but this study evaluated patients after 9 months of ART. Taken together, these data suggest that tissue RNA suppression is possible, albeit at a slower rate than plasma. While the clinical implications of time-tovirologic suppression within tissue remains unclear, it is possible that prolonged HIV persistence in tissue impacts immune activation and inflammatory cascades, potentially contributing to increased morbidity in an aging HIV cohort.
First dose and steady-state DTG AUC 0-24h were lower than previously reported data [6, 14, 15] , which may be because of our cohort being older with higher BMI, two factors associated with lower DTG exposure in a population pharmacokinetic study [16] . Median rectal tissue DTG concentrations were lower than paired plasma concentrations at all time points, consistent with literature reporting low rectal tissue concentrations relative to plasma in HIV seronegative men [6] . Effective distribution of drug into lymphatic tissues is dependent on drug physiochemical properties and intestinal expression of efflux transporters. First, hydrophobic drugs with log octanol water partition coefficient, log P, greater than 5 and high molecular weight have greater absorption via the gastrointestinal lymphatic system [17] . DTG lacks these characteristics, with a low molecular weight of 441.36 g/mol and log P of 2.16 [18] . Secondly, the intestinal expression of drug transporters changes with both HIV infection and ART initiation: gene and protein expression of p-glycoprotein is significantly increased in HIV-infected individuals receiving ART [19] . As a result, substrates for this transporter, such as DTG may have reduced transport into intestinal lymphatic tissues.
Despite low-DTG penetration into rectal tissue, neither DTG rectal tissue concentrations nor rectal : plasma concentration ratios were statistically significant predictors of rectal tissue RNA suppression, consistent with Rectal DTG concentrations were converted from ng/g to ng/ml assuming a tissue density of 1.06 ng/ml.
findings examining other primary non-INSTI medications [8] . As drug concentration assessments at single time points are limited snapshots of tissue drug exposure, we cannot completely rule out the possibility that suboptimal DTG concentrations affected rectal tissue viral dynamics in this study. Ideally, tissue drug AUC (0-24) over a single dosing interval would be measured; however, given the invasiveness of repeated tissue sampling, this type of analysis would only be possible using a population approach.
Our findings that rectal tissue nonsuppressors had higher baseline plasma and rectal tissue RNA viral loads than rectal tissue-suppressors suggest that these compartments are linked. Higher baseline plasma viral loads (>100 000 copies/ml) are associated with residual lowlevel viremia detectable by single-copy PCR assays [20] , and it is reasonable that this relationship would hold true in tissue sites. The finding of higher BMI in rectal tissue suppressors compared with rectal tissue nonsuppressors is new. Being overweight was associated with lower risk of HIV progression in both HIV-infected women and men [21, 22] , and higher BMI in women was associated with higher CD4 þ cell count and lower mean log viral load [22] . One theory is that the protective effect of obesity may be mediated by the immunomodulatory properties HIV RNA and DTG in rectal tissue Lahiri et al. 2157 of the hormone leptin [23] . Leptin levels are directly proportional to fat cell mass and tend to be higher in women than men, even at comparable body fat levels [24] . Interestingly, all three rectal tissue suppressors in this study were women. Although studies have shown that women have lower baseline plasma viral loads and faster time to plasma virologic suppression than men [25] , sex differences in HIV viral dynamics within tissues such as gut have not been well studied, largely because of the scarcity of women in HIV clinical research [26] . Mechanisms behind these differences have not been elucidated but theories include interactions between sex steroids and the immune system [27] . Although our sample size was too small to conduct sex-stratified analyses, future studies powered to examine sex differences in HIV viral dynamics within tissues are planned.
Our study had several limitations. First, sample size was small with n ¼ 12, limiting our ability to conduct multivariate analyses; nonetheless, participants provided 42 pairs of blood and tissue samples, allowing for robust assessments of viral dynamics and drug exposure not previously assessed in other studies. Second, adherence was self-reported in 50% of study visits, which is prone to recall bias. However, given that all participants attained plasma virologic suppression by week 6 with detectable DTG in 97% of blood and rectal tissue sample pairs, we can conclude that participants were routinely taking ART. Third, insufficient sampling of tissue could affect the ability to detect HIV RNA. Although this is theoretically possible, we quantified HIV RNA in 35 of 42 (83%) of rectal tissue samples, and two participants had undetectable rectal HIV RNA at three sequential time points. These consistent results suggest our findings were accurate and less likely because of inadequate sampling.
Furthermore, we quantitated DTG concentrations from rectal tissue homogenates rather than isolating rectal cells. As tissue homogenates are composed of both extracellular and intracellular components, concentrations overestimate exposure in drugs with intracellular modes of action, such as DTG [28] . However, our study paired tissue homogenate drug concentrations with objective measures of effectiveness (i.e. HIV RNA) at multiple time-points for each patient. Additionally, participants were receiving different NRTI backbones, and we did not measure NRTI drug concentrations. Although ideal, enrolling participants receiving identical NRTI backbones would have been impossible, given the subsequent approval of DTG/ABC/3TC and TAF/FTC mid-study. Although TDF has been shown to attain very high rectal : plasma tissue concentrations compared with other NRTIs [29] , three of five (60%) participants in our study receiving TDF/FTC had persistent detectable rectal tissue RNA. Even so, given the increasing use of TAF, an NRTI with significantly lower rectal tissue penetration [30] , further studies are needed to assess the impact of TAF exposure on tissue viral dynamics. Finally, we cannot infer from these results whether the HIV RNA recovered is infectious or capable of replication. Studies including quantitative viral outgrowth and infectivity assays are needed and currently underway.
In conclusion, plasma and rectal tissue HIV viral dynamics were discordant in the majority of participants initiating DTG-ART. Neither plasma nor rectal tissue DTG concentrations were statistically significant predictors of rectal tissue HIV RNA suppression, although larger population pharmacokinetic-pharmacodynamic studies are needed to assess the role of tissue drug exposure in tissue viral dynamics or HIV persistence. Future studies should explore mechanisms, particularly sex-mediated, that may explain differences in compartmental HIV viral dynamics and inform strategies to reduce the HIV tissue reservoir.
